Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1124.8000 -12.00 (-1.06%)
NSE Oct 14, 2025 15:31 PM
Volume: 1.0M
 

1124.80
-1.06%
Reliance Securities
Generis acquisition to strengthen ARBP's Europe business Aurobindo Pharma (ARBP) has acquired Generis Farmaceutica SA (Generis) for 135mn (including net working capital of 21.7mn) with reasonable valuation at 2.1x EV/Sales and 10.4x EV/EBITDA. With this acquisition (Generis SA: 2nd largest player by value), combined entity would become the largest player in Portuguese generic pharma market. In CY16, Generis generated 85% of sales from retail (73%) and hospital (12%) segment and have a well-diversified portfolio of 227 products, out of which 51 are pending for approval. Portuguese pharmaceutical market size is estimated at...
Aurobindo Pharma Ltd. is trading below its 150 day SMA of 1129.4
More from Aurobindo Pharma Ltd.
Recommended